Latest News

KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the identification and validation of a novel target, CT-1, for the development of engineered tumor infiltrating lymphocyte (eTIL™) therapies for refractory solid tumors. Data from two large-scale CRISPR-Cas9 functional screens using the com

Source link

Related posts

Measuring blood protein levels in diabetic patients to predict risk of stroke


A new deep learning approach to predict disease-associated mutations


Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World